FOR YOUR PATIENTS

Explaining the Envisia test to patients

The Envisia classifier is a genomic test that aids clinicians in differentiating between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD), without having to do a surgical lung biopsy.

How to explain Envisia to patients

The test analyzes lung tissue samples collected during a transbronchial biopsy (TBB), a nonsurgical procedure commonly used to diagnose lung diseases.

Logo depicting a lung bronchoscopy procedure in a lung with ILD lesions

A doctor collects 3-5 lung tissue samples during a nonsurgical transbronchial biopsy (TBB) and sends them to the lab.

Logo of a magnifying glass looking at a strand of DNA with potential alterations

The test looks at 190 genes commonly associated with fibrosis or inflammation.

Logo of a test results, showing negative checked, and a folder of medical files

The results indicate either positive or negative for usual interstital pneumonia (UIP), which helps guide next steps.

Photo of the patient handout

Patient handout

This handout may help healthcare professionals discuss the Envisia classifier with patients and how the test works.

Billing and reimbursement

Client services:
1.844.464.5864

Customer support:
support@veracyte.com

Covered by Medicare

The Envisia  test is covered by Medicare. Veracyte bills Medicare and third-party payers directly.

The Veracyte Access Program provides financial support for both eligible uninsured and commercially available insured patients with financial need.